Evidence map›Paper›PMID 41609942›Full record

ArticleCurrent protocols2026

Rapid, Scalable, and Cost-Effective Manufacturing of Uniform Non-Enveloped, Tag-Free Virus-Like Particles.

Xiaoyan Wang, Yanhao Gu, Hong Luo, Cinderella Nowak, Rui Chen, Yue Hui, Sha Liu, Lukas Gerstweiler

Erratum issuedAbstract read
In one paragraph

Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Xiaoyan WangSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.
Yanhao GuSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.
Hong LuoProtein Expression Facility, The University of Queensland, Brisbane, Australia.
Cinderella NowakSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.
Rui ChenSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.
Yue HuiSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.
Sha LiuSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.
Lukas GerstweilerSchool of Chemical Engineering, Adelaide University, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virus-like particles (VLPs) are widely recognized as safe and versatile nanostructures with broad applications in vaccine development, gene delivery, and nanotechnology, but their production typically requires time-consuming procedures, incurs high costs, and yields products of limited purity. This article outlines a rapid, scalable, and cost-effective method for producing high-quality VLPs using the VP1s capsid protein from murine polyomavirus. The procedure comprises four principal stages: expression of the capsid protein in Escherichia coli, extraction and stabilization of the protein, purification to yield high-quality capsomeres, and controlled in vitro assembly of VLPs. Compared with conventional protocols that rely on in vivo assembly and labor-intensive purification procedures, such as ultracentrifugation- or affinity tag-based methods, the described approach provides a streamlined and rapid workflow that avoids affinity tags, achieves consistently high yields, and enables precise regulation of assembly conditions, resulting in a scalable and highly cost-efficient strategy for VLP production within 5 days. © 2026 Wiley Periodicals LLC. Basic Protocol 1: Expression and preparation of polyomavirus VP1 protein in E. coli Basic Protocol 2: Polymomavirus VP1 purification Basic Protocol 3: VP1 assembly Basic Protocol 4: Quality control.

Indexed as

Capsid ProteinsVaccines, Virus-Like ParticleAnimalsCost-Benefit AnalysisEscherichia coliPolyomavirusCapsid ProteinsVaccines, Virus-Like ParticleVP1 protein, polyomavirusin vitro VLP assemblylow‐cost bioprocessingmultimodal chromatographypolyomavirus VP1virus‐like particlesVLP

Identifiers

PMID41609942
PMCPMC12915517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.